Nanobac Pharmaceuticals, Incorporated (OTCPK: NNBP)
Health Care · Biotechnology · US
$0.00
— today · 0.0% 1Y
Nanobac Pharmaceuticals, Incorporated (OTCPK: NNBP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $250.00 and employs 1 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Nanobac Pharmaceuticals, Incorporated across four factors: value 50/100. Its strongest factor is value.
NNBP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $250.00
- Revenue (TTM)
- $17.62K
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- -53.41
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 249.51M
- Employees
- 1
- Next earnings
- —
About Nanobac Pharmaceuticals, Incorporated
Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO. Furthermore, Nanobac engages in research and clinical studies focused on various urological diseases—such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases—as well as cardiovascular ailments. Established in 1994 and headquartered in Tampa, Florida, the company operated as HealthCentrics Inc. until its name change to Nanobac Pharmaceuticals, Incorporated in December 2002.
- ISIN
- US63007M1027
- Founded
- 1994
- Listed since
- Oct 31, 1994
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.